Logo
Revofil Fine 2x1ml

Revofil Fine 2x1ml

Revofil

Dermal filler (medical device)
  • CE Marked hyaluronic acid dermal filler (various listings indicate CE marking on outer box, including versions with lidocaine)
  • Manufactured under ISO 13485–compliant quality management system for medical devices
  • Produced according to Good Manufacturing Practice (GMP) standards
  • Biodegradable, non Animal Derived cross Linked hyaluronic acid with biomimetic peptide technology
  • Classified as a medical device for injection into the superficial dermis for correction of superficial wrinkles, fine lines and scars
Soft-touch cross-linked hyaluronic acid dermal filler for fine lines and superficial wrinkles

Description

Revofil Fine 2x1ml is a soft-touch, hyaluronic acid–based dermal filler with biomimetic peptide technology, developed by Caregen Co., Ltd. It is designed for precise correction of fine lines, superficial wrinkles and minor scars, as well as for delicate areas such as the perioral region and crow’s feet. The product combines cross-linked hyaluronic acid (23 mg/ml) with bioactive oligopeptides to enhance stability, prolong HA residence time and support collagen and HA synthesis, resulting in smoother, more hydrated and rejuvenated skin with natural, long-lasting results. The 2x1ml presentation provides both precision treatment and broader facial rejuvenation in one pack.

Bnefits

  • Targets fine lines, soft lines and superficial wrinkles with a soft, non-invasive gel texture
  • Helps correct caved or superficial scars and minor skin imperfections
  • Designed for delicate, precision areas (e.g. perioral region, crow’s feet, periocular area) as well as broader facial refinement
  • Combines cross-linked hyaluronic acid with biomimetic peptides for more natural and longer-lasting results than HA alone
  • Oligopeptide-72 helps inhibit HA degradation for more even, prolonged filler absorption over time
  • Oligopeptide-50 provides anti-inflammatory benefits and stimulates collagen and hyaluronic acid production in the skin
  • Improves hydration, elasticity and overall dermal quality for a refined, rejuvenated appearance
  • Soft, smooth gel integrates seamlessly into tissue and is easy to inject and mould
  • Minimally invasive procedure with immediate visible improvements and extended duration of effect

Indications

  • Fine lines and light wrinkles on the face
  • Superficial wrinkles (e.g. perioral lines, early crow’s feet)
  • Soft lines and minor skin depressions
  • Caved or fine scars (e.g. acne scars, superficial atrophic scars)
  • Perioral region and crow’s feet for precise, delicate enhancement
  • Tear troughs and under-eye area (bags / hollowing) depending on practitioner protocol and patient selection
  • Upper cheeks and hollow or slightly sunken cheeks
  • Light wrinkles and skin ageing on the backs of the hands
  • General superficial biorevitalisation and hydration of fine, crepey skin

Composition

  • Cross-linked sodium hyaluronate (hyaluronic acid) 23 mg/ml
  • Oligopeptide-72 (biomimetic peptide that helps inhibit hyaluronic acid degradation for smoother, more even and longer-lasting effects)
  • Oligopeptide-50 (biomimetic peptide with anti-inflammatory activity that increases collagen and hyaluronic acid in the skin)
  • Physiological buffer solution and standard injectable excipients
  • Some market variants are supplied with lidocaine and CE mark (e.g. 1 ml with lidocaine, CE 2265); the core formulation is cross-linked HA with biomimetic peptides

Formulation

  • Soft-touch, transparent, cross-linked hyaluronic acid gel
  • Monophasic / cohesive gel with peptide technology for improved stability and longevity
  • Optimised for superficial dermal injection and smooth tissue integration
  • Sterile, pyrogen-free, non-animal-derived HA-based dermal filler in prefilled syringes

Packaging

  • Box containing 2 x 1 ml prefilled glass syringes (total 2 ml)
  • Syringes typically supplied with 30G 1/2" needles (depending on market and distributor)
  • Each syringe individually blister-packed with instructions for use (IFU) and peel-off traceability labels

Usage

  • For professional use only; injection must be performed by appropriately trained and qualified medical/aesthetic practitioners.
  • Intended injection depth: superficial dermis for correction of fine and superficial wrinkles, soft lines and scars.
  • Common treatment areas include perioral region, crow’s feet, eyelids/tear troughs (where indicated), under-eye bags, upper cheeks, minor scars and light wrinkles on the backs of the hands.
  • Use strict aseptic technique: disinfect the skin thoroughly and maintain sterility of syringe, needle and treatment field.
  • Attach the supplied 30G needle (or equivalent fine-gauge needle or cannula) and expel air before injection.
  • Inject slowly with minimal pressure using appropriate superficial techniques such as linear threading, serial puncture or micro-depot injections, adapting the technique to the area and indication.
  • Gently massage the treated areas if required to evenly distribute the filler and smooth any irregularities.
  • Avoid intravascular injection and high-risk vascular zones; aspirate according to clinic protocol and monitor for any signs of vascular compromise.
  • Advise patients to avoid makeup on treated areas for several hours and to refrain from intense exercise, alcohol consumption, and exposure to excessive heat, cold or UV immediately after treatment, generally for 24 hours or as per clinic protocol.
  • Always follow the official Instructions for Use (IFU) provided with the product for detailed guidance on indications, technique, contraindications and precautions.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, any of the biomimetic peptides (e.g. Oligopeptide-72, Oligopeptide-50) or any excipient in the formulation
  • History of severe or multiple allergies or anaphylactic reactions unless carefully evaluated and cleared by a physician
  • Presence of active skin infection, inflammation or dermatologic disease at or near the intended injection site (e.g. herpes simplex, active acne, dermatitis)
  • Systemic infection or uncontrolled systemic disease where dermal filler treatments are inappropriate
  • Autoimmune diseases or immunocompromised conditions unless the risk–benefit is individually assessed by the treating clinician
  • Pregnancy and breastfeeding (generally not recommended in the absence of robust safety data for this product group)
  • Tendency to develop hypertrophic or keloid scars or significantly impaired wound healing
  • Use in patients under 18 years of age
  • Planned injection into or near blood vessels or in high-risk vascular areas without appropriate expertise and precautions

Adverse Effects

  • Common, usually transient injection-site reactions such as redness (erythema), swelling, tenderness, pain, itching, and minor bruising or bleeding
  • Temporary nodules, small papules, irregularities or asymmetry at the injection area, often resolving spontaneously or with gentle massage or minor correction
  • Localised infection or abscess formation if aseptic technique is not strictly followed
  • Immediate or delayed hypersensitivity or inflammatory reactions, including swelling, erythema, induration or pruritus
  • Very rare but serious complications typical of HA fillers, such as vascular occlusion, tissue ischemia or necrosis, and visual disturbances or blindness if material is inadvertently injected into a blood vessel; these events require urgent medical assessment and management
  • Any persistent, unusual or severe adverse event should be promptly evaluated and treated by a qualified medical professional

Storage Conditions

  • Store according to the manufacturer’s labelling, typically at controlled room temperature (for example 2–25 °C or 2–30 °C depending on packaging)
  • Do not freeze
  • Protect from direct sunlight and excessive heat
  • Keep the syringes in their original sterile blister and outer carton until use to maintain sterility and traceability
  • Do not use if the blister pack, syringe or outer carton is damaged, previously opened, or after the expiry date printed on the packaging
  • Keep out of the reach of children

Duration

Maintenance period is typically reported at around 8\u201310 months on average, depending on treatment area, injection technique, patient metabolism, lifestyle and skin condition.

Onset

Visible correction and skin smoothing are usually immediate after injection, with final aesthetic results becoming apparent once initial swelling or redness has subsided over the following days.

Browse more Dermal filler (medical device)

Top Treatments

Top Cities in the UK